Stage III NSCLC RWE in Chinese Patients

Study identifier:D4194R00009

ClinicalTrials.gov identifier:NCT04023812

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Real-World Molecular Testing, Treatment Patterns and Clinical Outcomes in Chinese Patients with Stage III NSCLC- A Prospective, Non-Interventional Study(MOOREA)

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

500

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 16 Jul 2019
Primary Completion Date: 29 Feb 2024
Study Completion Date: 29 Feb 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria